GSK's Blenrep is re-entering the multiple myeloma treatment landscape with a new BLA submission to the FDA for combination therapy. Based on successful Phase III trials, the drug is expected to compete with other BCMA-targeted treatments, offering advantages over CAR-T therapy.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing